4-nitro-N-[4-(pyridin-4-ylamino)phenyl]benzamide | 23552-71-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-nitro-N-[4-(pyridin-4-ylamino)phenyl]benzamide
• CAS: 23552-71-8
• 化学式: C₁₈H₁₄N₄O₃
• 分子量: 334.334
• InChiKey: LXRNPLQXTWJKIP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  99.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-nitro-N-[4-(pyridin-4-ylamino)phenyl]benzamide 在 1-X₄, BioRad AG, 200-400 chloride form 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 生成 1-methyl-4-((4-(4-nitrobenzamido)phenyl)amino)pyridin-1-ium chloride
  参考文献：
  名称：

  Structure–activity relationships for 4-anilinoquinoline derivatives as inhibitors of the DNA methyltransferase enzyme DNMT1

  摘要：

  A series of 4-anilinoquinoline derivatives related to the known inhibitor SGI-1027, containing side chains of varying pK(a), were prepared by acid-catalysed coupling of the pre-formed side chains with 4-chloroquinolines. The compounds were evaluated for their ability to reduce the level of DNMT1 protein in HCT116 human colon carcinoma cells by Western blotting. With a very strongly basic N-methylpyridinium side chain, only NHCO-linked compounds were effective, whereas less strongly basic ((diaminomethylene) hydrazono)ethyl or 3-methylpyrimidine-2,4-diamine side chains allowed both NHCO- and CONH-linked compounds to show activity. In contrast, the pK(a) of the quinoline unit had little apparent influence on activity. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.03.033
• 作为产物：
  描述：

  4-吡啶基氯化吡啶 在 吡啶 、 铁粉 、 对甲苯磺酸 、 苯酚 作用下， 以 1,4-二氧六环 、 乙醇 、 水 、 溶剂黄146 、 苯 为溶剂， 反应 4.5h， 生成 4-nitro-N-[4-(pyridin-4-ylamino)phenyl]benzamide
  参考文献：
  名称：

  Structure–activity relationships for 4-anilinoquinoline derivatives as inhibitors of the DNA methyltransferase enzyme DNMT1

  摘要：

  A series of 4-anilinoquinoline derivatives related to the known inhibitor SGI-1027, containing side chains of varying pK(a), were prepared by acid-catalysed coupling of the pre-formed side chains with 4-chloroquinolines. The compounds were evaluated for their ability to reduce the level of DNMT1 protein in HCT116 human colon carcinoma cells by Western blotting. With a very strongly basic N-methylpyridinium side chain, only NHCO-linked compounds were effective, whereas less strongly basic ((diaminomethylene) hydrazono)ethyl or 3-methylpyrimidine-2,4-diamine side chains allowed both NHCO- and CONH-linked compounds to show activity. In contrast, the pK(a) of the quinoline unit had little apparent influence on activity. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.03.033

文献信息

• [EN] AKT3 MODULATORS<br/>[FR] MODULATEURS DE AKT3
  申请人：GEORGIAMUNE LLC

  公开号：WO2021226519A1

  公开（公告）日：2021-11-11

  Compounds of Formula la, lb, or Ic, are described, where the various substituents are defined herein. The compounds can modulate a property or effect of Akt3 in vitro or in vivo, and can also be used, individually or in combination with other agents, in the prevention or treatment of a variety of conditions. Methods for synthesizing the compounds are described. Pharmaceutical compositions and methods of using these compounds or compositions, individually or in combination with other agents or compositions, in the prevention or treatment of a variety of conditions are also described.

  公式Ia、Ib或Ic的化合物已被描述，其中各种取代基在此定义。这些化合物可以在体外或体内调节Akt3的性质或效果，并且也可以单独或与其他药剂结合在预防或治疗各种疾病方面使用。描述了合成这些化合物的方法。还描述了制药组合物以及使用这些化合物或组合物在预防或治疗各种疾病中单独或与其他药剂或组合物结合的方法。
• QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION
  申请人：Phiasivongsa Pasit

  公开号：US20090285772A1

  公开（公告）日：2009-11-19

  Quinoline derivatives, particularly 4-anilinoquinoline derivatives, are provided. Such quinoline derivatives can be used for modulation of DNA methylation, such as effective inhibition of methylation of cytosine at the C-5 position, for example via selective inhibition of DNA methyltransferase DNMT1. Methods for synthesizing numerous 4-anilinoquinoline derivatives and for modulating DNA methylation are provided. Also provided are methods for formulating and administering these compounds or compositions to treat conditions such as cancer and hematological disorders.

  提供了喹啉衍生物，特别是4-苯胺基喹啉衍生物。这样的喹啉衍生物可用于调节DNA甲基化，例如通过选择性抑制DNA甲基转移酶DNMT1，有效抑制C-5位置的胞嘧啶甲基化。提供了合成多种4-苯胺基喹啉衍生物和调节DNA甲基化的方法。还提供了制剂和给药这些化合物或组合物以治疗癌症和血液疾病的方法。
• WO2008/46085
  申请人：——

  公开号：——

  公开（公告）日：——
• US7790746B2
  申请人：——

  公开号：US7790746B2

  公开（公告）日：2010-09-07
• US7939546B2
  申请人：——

  公开号：US7939546B2

  公开（公告）日：2011-05-10